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CASE STUDY
Successful pregnancy and delivery in a 
patient with chronic myeloid leukemia: a case 
report and review of the literature
Weiwei Sheng and Naitong Sun*
Abstract 
Introduction: Complications associated with chronic myeloid leukemia (CML) during pregnancy are rare, and man-
agement is challenging because very limited data are available on this patient group.
Case description: We herein report a successful pregnancy and delivery in a patient diagnosed with CML. The 
patient was treated with imatinib (400 mg/day) as a first-line therapy. However, she became pregnant while she was 
in complete hematological remission and had a complete cytogenetic response. Because she elected to continue 
the pregnancy to term, imatinib treatment was stopped after 5 months of gestation and the patient was then treated 
with interferon-alpha for the remainder of her pregnancy. However, the CML did not relapse. She successfully gave 
birth to a male infant at 39 weeks by cesarean section with no adverse sequelae or malformations.
Discussion and Evaluation: The treatment of pregnant women with CML is difficult because of few available 
therapeutic options and limited data regarding the potential harm to the fetus. Conception should be planned and 
TKI therapy discontinued in female patients during pregnancy, and individual risks need to be considered when an 
unplanned pregnancy occurs.
Conclusions: Our experience will be useful for counseling patients inadvertently exposed to tyrosine kinase inhibi-
tors such as imatinib during pregnancy.
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Background
Chronic myeloid leukemia (CML) accounts for about 15% 
of cases of adult leukemia, and its median age of onset is 
about 67 years (O’Brien et al. 2011). Approximately 4870 
cases of CML were diagnosed in the US in the year 2010, 
and 440 of these patients died of CML (Jemal et al. 2010). 
CML is a hematopoietic stem cell disease caused by a 
reciprocal translocation between chromosomes 9 and 
22, leading to the formation of the Philadelphia chromo-
some (Ph). The translocation t(9:22) results in the head-
to-tail fusion of the breakpoint cluster region (BCR) gene 
on chromosome 22 at band q11 with the Abelson murine 
leukemia (ABL) gene located on chromosome 9 at band 
q34 (Faderl et  al. 1999). The product of the fusion gene 
(BCR/ABL) has been confirmed to play a central role in 
the development of CML (Daley et al. 1990). The recent 
use of tyrosine kinase inhibitors (TKIs) in patients with 
CML has transformed this disease from a fatal condition 
without aggressive intervention to a chronic condition 
associated with an extended life expectancy (Hensley 
and Ford 2003). Therefore, administration of TKIs has 
become the first-line therapy for patients newly diag-
nosed with CML. It is rare to encounter a pregnant 
patient with CML because the median age at the time of 
diagnosis is approximately 60 years. The main challenge 
in the use of TKIs to treat pregnant patients with CML is 
the teratogenic risk for the fetus (Doll et al. 1988). There-
fore, although such treatment should be stopped during 
pregnancy, this may increase the chance of relapse and 
influence disease progression.
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Case presentation
In June 2003, a 22-year-old woman was diagnosed with a 
Ph +  karyotype and chronic CML. Her physical exami-
nation results were normal upon hospital admission. 
Her peripheral blood test results were as follows: white 
blood cell count of 227  ×  109/L with 2% blasts, 20% 
myelocytes, 10% metamyelocytes, 12% bands, 53% neu-
trophils, and 3% lymphocytes; hemoglobin concentra-
tion of 79 g/L; and platelet count of 201 × 109/L. Renal 
and liver test results were normal. The diagnosis of CML 
was confirmed based on detection of BCR/ABL mRNA 
transcripts and chromosome banding, which revealed 
a 46, XY, t(9;22) karyotype. She was first treated with 
hydroxyurea (2  g/day) and obtained a complete hema-
tologic response (CHR) with no cytogenetic response 
within 6  months. After 6  months, she was presented to 
FUNDALEU hospital and began treatment with imatinib 
(400  mg/day) as a first-line treatment with good toler-
ance and adherence to the medication. She obtained a 
major molecular response (MMR) in 12  months. Poly-
merase chain reaction (PCR) amplification for the BCR/
ABL sequence was checked every 6  months to confirm 
the persistence of the MMR. Although the patient had 
been advised to use effective methods of contraception 
during therapy, she reported having had amenorrhea 
for 2  months in July 2006. Ultrasonography revealed 
pregnancy at 5  weeks of gestation. Although no data 
were available to us regarding stopping TKI treatment 
during pregnancy, after being informed of the possi-
ble risks, the patient and her relatives chose to continue 
imatinib therapy during the first 5  months of gestation. 
At that point, the imatinib treatment was stopped and 
the patient was treated with interferon-alpha (IFN-α) at 3 
million IU twice a week throughout the remaining preg-
nancy. All follow-up ultrasound scans during the course 
of the pregnancy were unremarkable. During pregnancy, 
the patient maintained the CHR (white blood cell count 
of <10 × 109/L without splenomegaly); karyotyping and 
molecular detection were not performed. On 14 February 
2007, the patient delivered a healthy male infant at gesta-
tional week 39 via cesarean section. The infant weighed 
3.2 kg with an Apgar score of 9 at 10 min. Moreover, the 
child was healthy and developed normally without any 
evidence of congenital malformations. Two months after 
delivery, the patient’s peripheral blood counts, mRNA 
transcripts of BCR/ABL by qualitative PCR, and kar-
yotype were normal. Imatinib treatment (400  mg/day) 
was restarted to prevent the recurrence of CML. Dur-
ing the next 8  years of follow-up (until the time of this 
writing), the patient has been adherent to the imatinib 
therapy and has maintained the CHR and MMR. The 
child was breast-fed for 1 month, remained healthy, and 
developed normally without any evidence of congenital 
malformations. The child’s peripheral blood tests and 
BCR/ABL mRNA transcripts were assessed every 3 years 
and showed normal results.
This study was approved by the Ethics Committee of 
the Third People’s Hospital of Yancheng. Informed writ-
ten consent was obtained from the patient in accordance 
with the Declaration of Helsinki.
Discussion
During the past decade, the clinical view of CML has 
changed dramatically to a disease requiring lifelong med-
ication that provides substantial disease control, rela-
tively few adverse effects, and nearly normal lifestyles for 
most patients. In 2001, the first TKI used for the front-
line treatment of CML, imatinib, was introduced into 
the US market, offering durable remission in up to 70% 
of patients. Dasatinib and nilotinib quickly followed as 
second-generation TKIs with additional targets.
In general, malignancy during pregnancy is a unique 
challenge for medical oncologists. When a woman 
becomes pregnant during chemotherapy or radiother-
apy, most cytotoxic agents and radiotherapy have many 
potential adverse side effects on the fetus (Buekers and 
Lallas 1998; Zuazu et al. 1991). In addition, many physi-
ological changes that occur during pregnancy (such 
as an increased plasma volume, a third space created 
by amniotic fluid, hepatic oxidation, and alterations in 
renal clearance) can affect drug distribution, metabo-
lism, and excretion (Weisz et  al. 2004; Cardonick et  al. 
2010). Moreover, chemotherapy reportedly inhibited the 
migration and proliferation of trophoblasts in first tri-
mester human placental explants, which might partially 
explain the lower birth weights of infants whose mothers 
received chemotherapy (Matalon et al. 2005).
Overall, malignant diseases are diagnosed in 0.1% of 
all pregnancies (Slade and James 1991; Rothman et  al. 
1973). The incidence of leukemia during pregnancy is 
approximately 1 in 75,000–100,000 pregnancies (Litcht-
man 1995), most cases of which are acute myeloid leuke-
mia or acute lymphoblastic leukemia. Treatment of CML 
during pregnancy is difficult because of limited available 
therapeutic options and the paucity of data regarding 
potential harm to the fetus. No therapy offered to preg-
nant women is both completely safe and effective; thus, 
clinicians are faced with the challenge of balancing the 
safety of the mother while treating her cancer against the 
safety of the unborn baby. Termination of pregnancy is 
considered a safe option for the mother in the first tri-
mester but was not desired in the present case. Because 
some women with CML are of childbearing age, they 
often raise issues relating to pregnancy. Therefore, man-
agement of the pregnancy should begin from the time of 
diagnosis of CML, and such patients should be informed 
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of the risks of therapy during pregnancy (Baccarani et al. 
2013). At the time of our experience (July 2006), very 
limited data were available regarding the treatment of 
women who conceive while undergoing TKI therapy. 
In March 2006, Ault et  al. (2006) reported that three 
women treated with imatinib had normal pregnancies. 
The first systematic review of imatinib treatment during 
pregnancy was reported by Pye et  al. (2008), who col-
lected information on 180 women exposed to imatinib 
during pregnancy among different institutions. The 
data showed that although most pregnancies in women 
exposed to imatinib had a successful outcome, exposure 
was still associated with a risk of serious fetal malforma-
tions. Because imatinib inhibits both tyrosine kinases and 
BCR/ABL expression, it is conceivable that congenital 
abnormalities might result from the inhibition of mem-
bers of this extensive enzyme family. Russell et al. (2007) 
described two pregnancies in women exposed to imatinib 
during the third trimester. Imatinib was found to be pre-
sent at high concentrations in the maternal blood and 
placenta; however, minimal or no drug was detected in 
the cord blood, suggesting that imatinib and its active 
metabolite cross the mature placenta only poorly. 
Since then, many similar cases have been reported, and 
patients treated with newer TKIs during pregnancy have 
also been recently described. One patient treated with 
nilotinib at 400  mg/day until 7.4  weeks of pregnancy 
delivered an infant with no identified congenital malfor-
mations, and the infant had normal development upon 
follow-up (Conchon et al. 2009). Based on clinical trials 
and animal experiments, Cortes et al. (2015) reported no 
apparent risk in the offspring of a small sample of dasat-
inib-treated men. However, in women treated with dasat-
inib, risks to the fetus were present in the form of skeletal 
malformations and detrimental pharmacological effects.
A pregnancy should only be planned after the mile-
stone of a stable complete cytogenetic response or better 
has been reached from at least 18–24 weeks of gestation. 
Ultrasonography and planned conception are highly rec-
ommended. Therapy should be stopped immediately 
before or immediately after conception. All TKIs must be 
avoided during the organogenesis phase (postmenstrual 
days 31–71, gestational weeks 5–13). PCR detection 
must be carried out each month or every 2 months to fol-
low the transcript, depending on the molecular biology 
results (Santorsola and Abruzzese 2015).
If a cytogenetic or hematologic relapse occurs during 
pregnancy without therapy, the patient should be evalu-
ated on an individual basis with respect to the rapidity of 
the relapse, the patient’s clinical history, and especially the 
pregnancy status (weeks of gestation). If necessary, consid-
ering the low degree of passage of imatinib and nilotinib 
into the fetal compartment, imatinib and nilotinib ther-
apy can be considered after the placenta has formed and 
organogenesis has been completed (Webb and Jafta 2012), 
while dasatinib therapy should be avoided throughout 
pregnancy because it can pass to the placenta (Berveil-
ler et al. 2012). Importantly, there is not enough evidence 
to support this hypothesis, and the use of any TKI at any 
stage of pregnancy is prohibited according to the manu-
facturers’ instructions. The risk of using a TKI, even in the 
third trimester, should be fully discussed with the patient 
and their partner and might only be justified if the woman 
is experiencing progression to an advanced phase of CML. 
In the present case, although the patient conceived acci-
dently and was treated with imatinib for the first 5 months 
of gestation, the child was closely monitored for more than 
8 years and no side effects or abnormal development were 
found. However, we still believe that effective contracep-
tion and planned pregnancy should be suggested during 
treatment with imatinib. The mother and child in this case 
are continuing to undergo follow-up.
The use of IFN-α could be an option when stopping 
TKI therapy in women with a suboptimal response. The 
maternal IFN-α concentration during pregnancy should 
be safe for the fetus, and IFN therapy during pregnancy 
could have the same outcomes as in nonpregnant women 
(Pons et al. 1995). IFN-α treatment does not significantly 
increase the risk of major malformations, miscarriage, 
stillbirth, or preterm delivery above that in the general 
population (Brojeni et  al. 2012). Therefore, treatment 
with IFN-α during medium-term and terminal gestation 
in pregnant women with CML is considered safe. IFN-α 
inhibits cell proliferation through its effects on protein 
synthesis and RNA breakdown and possibly by immu-
nomodulation. Because of its high molecular weight 
(19 kDa), it does not cross the placental barrier. However, 
IFN-α does not inhibit DNA synthesis (Baer et al. 1992). 
Mutagenicity and teratogenicity have not been observed 
in animal studies of this agent (Mubarak et al. 2002). Sev-
eral case reports of IFN-α treatment during pregnancy 
in women with CML have been published, and no con-
genital abnormalities in their infants have been reported 
(Regierer et al. 2006; Al Bahar et al. 2004). Based on our 
experience, IFN-α therapy appears to be safe in the sec-
ond and third trimesters of pregnancy. However, whether 
to use a TKI or IFN-α in the first trimester was difficult 
to decide because imatinib therapy is not absolutely 
safe for the fetus (Palani et  al. 2015). In this case, when 
we became aware that imatinib therapy might adversely 
affect the fetus, IFN-α at 3 million IU twice a week was 
used throughout the remaining pregnancy. The reassur-
ing follow-up findings during the past 8 years have sug-
gested a good outcome for this treatment.
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The latest progress in CML treatment has signifi-
cantly improved survival and provides most patients 
with a durable MMR and quality of life. However, the 
management of CML during pregnancy remains a clini-
cal challenge. We cannot deny that imatinib therapy 
during pregnancy is associated with an increased risk 
of spontaneous abortions and serious congenital mal-
formations. Abruzzese et  al. (2016) recently presented 
a complete review on the subject; they suggested that 
treatment with TKIs has no limitations in male patients 
trying to conceive, while effective contraception should 
be encouraged in all female patients because of the risk 
of fetal complications associated with drug exposure. 
Conception should be planned and TKI therapy discon-
tinued in female patients during pregnancy, and indi-
vidual risks need to be considered when an unplanned 
pregnancy occurs. Women of childbearing age should 
be advised to apply effective contraceptive measures to 
avoid conceiving during treatment with TKIs. Women 
wishing to discontinue treatment to conceive should 
be counseled and advised of the risk of an adverse 
response or relapse even if they have achieved a pro-
found and lasting MMR. Molecular monitoring should 
be carried out at regular intervals throughout preg-
nancy and consideration given to introducing IFN-α 
if there is any increase in the tumor load. Overall, our 
experience will be useful in counseling patients inad-
vertently exposed to TKIs during pregnancy. The first 
international register of pregnancy outcomes including 
details regarding the treatment type (imatinib, other 
TKIs, and drugs) has been established by the European 
Leukemia Network. We hope that the treatment of 
women with CML of childbearing age will be increas-
ingly standardized.
Conclusions
Although the treatment of CML during pregnancy poses 
a significant challenge for physicians, and although this 
particular experience was limited to a single patient, the 
successful outcome in the present case suggests that the 
management of pregnancy in patients undergoing treat-
ment with TKIs should be individualized and based on 
a balance between the relative risks and benefits to the 
patient and fetus.
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